LBLTF (Lattice Biologics) Total Current Liabilities: $0.51 Mil (As of Jun. 2021)


What is Lattice Biologics Total Current Liabilities?

Lattice Biologics LBLTF -99.00% Total Current Liabilities is $0.51 Mil as of Jun. 2021.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Lattice Biologics's total current liabilities for the quarter that ended in Jun. 2021 was $0.51

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Lattice Biologics Total Current Liabilities Related Terms

Lattice Biologics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Total Current Liabilities Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.79 6.53 6.97 7.69 7.83

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 7.83 7.99 1.53 0.51

Lattice Biologics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Lattice Biologics's Total Current Liabilities for the fiscal year that ended in Sep. 2020 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.211+2.247
+Other Current Liabilities+Current Deferred Liabilities
=0.374+0
=7.83

Lattice Biologics's Total Current Liabilities for the quarter that ended in Jun. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.506+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $0.51 Mil mean?
Lattice Biologics (LBLTF) has a Total Current Liabilities of $0.51 Mil as of Jun. 2021. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Lattice Biologics and its competitors.
Is Lattice Biologics' Total Current Liabilities too high?
Lattice Biologics' current Total Current Liabilities is $0.51 Mil.
How does Lattice Biologics' Total Current Liabilities compare to ABT and MDT?
Lattice Biologics' Total Current Liabilities of $0.51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Lattice Biologics and its competitors. Lattice Biologics's current Total Current Liabilities is $0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Total Current Liabilities of $0.51 Mil. The current Total Current Liabilities is $0.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Total Current Liabilities is $0.51 Mil as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.